Kurt Fahrenbrook, AUD, CCC-A | |
2 W 42nd St, Suite 1100, Scottsbluff, NE 69361-4669 | |
(308) 635-3155 | |
(308) 635-2966 |
Full Name | Kurt Fahrenbrook |
---|---|
Gender | Male |
Speciality | Qualified Audiologist |
Experience | 23 Years |
Location | 2 W 42nd St, Scottsbluff, Nebraska |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1841214509 | NPI | - | NPPES |
123 | Medicaid | NE | |
640002691 | Other | NE | PALMENTO GBA RR MEDICARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | 123 (Nebraska) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Regional West Physicians Clinic | 2062301609 | 114 |
News Archive
No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA. No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA.
Angiosarcoma Project, a patient-partnered genomics study, identified immune checkpoint inhibition as a potential treatment option for patients with angiosarcomas of the head, face, neck, or scalp, according to data presented at the fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.
A Case Western Reserve University scientist, who has for more than a decade pioneered research into synthetic platelet substitutes, has been awarded a $3.8 million grant by the U.S. Department of Defense (DOD) to develop freeze-dried artificial platelets that can treat bleeding in wounded soldiers in the battlefield before they can be taken to a hospital.
› Verified 9 days ago
Provider Name | Regional West Physicians Clinic |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1306910534 PECOS PAC ID: 2062301609 Enrollment ID: O20040315001274 |
News Archive
No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA. No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA.
Angiosarcoma Project, a patient-partnered genomics study, identified immune checkpoint inhibition as a potential treatment option for patients with angiosarcomas of the head, face, neck, or scalp, according to data presented at the fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.
A Case Western Reserve University scientist, who has for more than a decade pioneered research into synthetic platelet substitutes, has been awarded a $3.8 million grant by the U.S. Department of Defense (DOD) to develop freeze-dried artificial platelets that can treat bleeding in wounded soldiers in the battlefield before they can be taken to a hospital.
› Verified 9 days ago
Provider Name | Western Ent Associates, Pc |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1538183207 PECOS PAC ID: 6800878794 Enrollment ID: O20050316000135 |
News Archive
No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA. No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA.
Angiosarcoma Project, a patient-partnered genomics study, identified immune checkpoint inhibition as a potential treatment option for patients with angiosarcomas of the head, face, neck, or scalp, according to data presented at the fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.
A Case Western Reserve University scientist, who has for more than a decade pioneered research into synthetic platelet substitutes, has been awarded a $3.8 million grant by the U.S. Department of Defense (DOD) to develop freeze-dried artificial platelets that can treat bleeding in wounded soldiers in the battlefield before they can be taken to a hospital.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Kurt Fahrenbrook, AUD, CCC-A 1600 Beverly Blvd, Gering, NE 69341-1914 Ph: (308) 635-3155 | Kurt Fahrenbrook, AUD, CCC-A 2 W 42nd St, Suite 1100, Scottsbluff, NE 69361-4669 Ph: (308) 635-3155 |
News Archive
No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA. No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA.
Angiosarcoma Project, a patient-partnered genomics study, identified immune checkpoint inhibition as a potential treatment option for patients with angiosarcomas of the head, face, neck, or scalp, according to data presented at the fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.
A Case Western Reserve University scientist, who has for more than a decade pioneered research into synthetic platelet substitutes, has been awarded a $3.8 million grant by the U.S. Department of Defense (DOD) to develop freeze-dried artificial platelets that can treat bleeding in wounded soldiers in the battlefield before they can be taken to a hospital.
› Verified 9 days ago